Photo from wikipedia
Erythropoiesis‐stimulating agents (ESAs), are used for treating chronic kidney disease (CKD)‐related anemia, contributing to CKD costs. The study was aimed at investigating direct healthcare costs of CKD patients treated with… Click to show full abstract
Erythropoiesis‐stimulating agents (ESAs), are used for treating chronic kidney disease (CKD)‐related anemia, contributing to CKD costs. The study was aimed at investigating direct healthcare costs of CKD patients treated with ESAs and the potential savings achievable by increasing the use of biosimilars and preventing inappropriate ESA use.
Keywords:
use;
chronic kidney;
direct healthcare;
erythropoiesis stimulating;
stimulating agents;
kidney disease
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!